{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:28:21Z","timestamp":1790080101312,"version":"4.0.1"},"reference-count":294,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,19]],"date-time":"2016-10-19T00:00:00Z","timestamp":1476835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AstraZeneca, Gaithersburg, MD, USA"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.pharmthera.2016.10.016","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T22:49:33Z","timestamp":1477003773000},"page":"57-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation"],"prefix":"10.1016","volume":"169","author":[{"given":"John","family":"Nixon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Newbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Mustelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary P.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Kolbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2016.10.016_bb0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13613-014-0032-x","article-title":"Systemic corticosteroids in acute exacerbation of COPD: A meta-analysis of controlled studies with emphasis on ICU patients","volume":"4","author":"Abroug","year":"2014","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0010","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1084\/jem.190.10.1465","article-title":"Ovalbumin sensitization changes the inflammatory response to subsequent parainfluenza infection. Eosinophils mediate airway hyper-responsiveness, m(2) muscarinic receptor dysfunction, and antiviral effects","volume":"190","author":"Adamko","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0015","doi-asserted-by":"crossref","first-page":"020415","DOI":"10.7189\/jogh.05.020415","article-title":"Global and regional estimates of COPD prevalence: Systematic review and meta-analysis","volume":"5","author":"Adeloye","year":"2015","journal-title":"J Glob Health"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0020","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1164\/ajrccm.161.5.9906052","article-title":"Effects of terbutaline and budesonide on sputum cells and bronchial hyper-responsiveness in asthma","volume":"161","author":"Aldridge","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1084\/jem.20062211","article-title":"Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells","volume":"204","author":"Allakhverdi","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0030","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jaci.2008.10.022","article-title":"CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation","volume":"123","author":"Allakhverdi","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0035","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.rmed.2013.12.012","article-title":"Anxiety, depression and personality traits in severe, prednisone-dependent asthma","volume":"108","author":"Amelink","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0040","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(08)61452-X","article-title":"Endotyping asthma: New insights into key pathogenic mechanisms in a complex, heterogeneous disease","volume":"372","author":"Anderson","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0045","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","article-title":"Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects","volume":"44","author":"Arm","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0050","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1378\/chest.129.3.565","article-title":"Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients","volume":"129","author":"Bacci","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0055","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1164\/ajrccm.160.5.9810105","article-title":"Eosinophilic inflammation in stable chronic obstructive pulmonary disease. Relationship between neutrophils and airway function","volume":"160","author":"Balzano","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0060","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"SIRIUS investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0065","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1136\/thx.2006.073429","article-title":"Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma","volume":"62","author":"Berry","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-3024.1999.00200.x","article-title":"Mast cells, eosinophils and antibody-mediated cellular cyto-toxicity are not critical in resistance to Trichuris muris","volume":"21","author":"Betts","year":"1999","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0075","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00011-004-1321-x","article-title":"Sputum eosinophilia in idiopathic pulmonary fibrosis","volume":"54","author":"Birring","year":"2005","journal-title":"Inflamm Res"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0085","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jaci.2012.01.059","article-title":"Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines","volume":"129","author":"Bossley","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0090","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","article-title":"Eosinophilic inflammation in asthma","volume":"323","author":"Bousquet","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0095","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","article-title":"Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: A randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Brightling","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0100","doi-asserted-by":"crossref","first-page":"713","DOI":"10.4155\/cli.15.36","article-title":"MESOS: Considerations in designing a mechanistic study for a biologic used to treat asthma","volume":"5","author":"Brightling","year":"2015","journal-title":"Clin Investig"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0105","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(14)70187-0","article-title":"Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: A randomised, double-blind, placebo-controlled, phase 2a study","volume":"2","author":"Brightling","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0110","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(58)91385-0","article-title":"Treatment of chronic asthma with prednisolone: Significance of eosinophils in the sputum","volume":"2","author":"Brown","year":"1958","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bmj.3.5872.161","article-title":"Beclomethasone dipropionate steroid aerosol in treatment of perennial allergic asthma in children","volume":"3","author":"Brown","year":"1973","journal-title":"Br Med J"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0120","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/bmj.1.5800.585","article-title":"Beclomethasone dipropionate: A new steroid aerosol for the treatment of allergic asthma","volume":"1","author":"Brown","year":"1972","journal-title":"Br Med J"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0125","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0130","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jaci.2010.04.005","article-title":"Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma","volume":"125","author":"Busse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0135","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaci.2013.02.032","article-title":"High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects","volume":"132","author":"Busse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0140","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/01.pec.0000144914.78124.6f","article-title":"Adherence of pediatric asthma patients with oral corticosteroid prescriptions following pediatric emergency department visit or hospitalization","volume":"20","author":"Butler","year":"2004","journal-title":"Pediatr Emerg Care"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0145","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/256727a0","article-title":"Eosinophils as mediators of antibody-dependent damage to schistosomula","volume":"256","author":"Butterworth","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0150","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/bjp.2008.362","article-title":"COPD: What is the unmet need?","volume":"155","author":"Calverley","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0155","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: A randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0160","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: A phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0165","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: Results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0170","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0175","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007949.pub2","article-title":"Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children","volume":"11","author":"Chauhan","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0185","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.jaci.2008.04.005","article-title":"A novel IL-1 family cytokine, IL-33, potently activates human eosinophils","volume":"121","author":"Cherry","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0190","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/147323000603400202","article-title":"Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma","volume":"34","author":"Chlumsk\u00fd","year":"2006","journal-title":"J Int Med Res"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011032.pub2","article-title":"Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults","volume":"7","author":"Chong","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0200","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/eji.201141953","article-title":"Immunization induces activation of bone marrow eosinophils required for plasma cell survival","volume":"42","author":"Chu","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ni.1981","article-title":"Eosinophils are required for the maintenance of plasma cells in the bone marrow","volume":"12","author":"Chu","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0210","author":"Cinqair [United States package insert]"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0215","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1084\/jem.182.4.1169","article-title":"Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo","volume":"182","author":"Collins","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0220","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/archpedi.155.10.1111","article-title":"Corticosteroid prescription filling for children covered by Medicaid following an emergency department visit or a hospitalization for asthma","volume":"155","author":"Cooper","year":"2001","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0225","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11882-013-0373-9","article-title":"Role of interleukin-13 in asthma","volume":"13","author":"Corren","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0230","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","volume":"365","author":"Corren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: Effects across a broad range of eosinophil counts","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0240","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1182\/blood.V77.7.1462.1462","article-title":"Interleukin-5 is a human basophilopoietin: Induction of histamine content and basophilic differentiation of HL-60 cells and of peripheral blood basophil-eosinophil progenitors","volume":"77","author":"Denburg","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0245","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jaci.2004.12.1129","article-title":"Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids","volume":"115","author":"Deykin","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0250","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1081\/JAS-120017986","article-title":"Analysis of sputum cell counts during spontaneous moderate exacerbations of asthma in comparison to the stable phase","volume":"40","author":"Di Franco","year":"2003","journal-title":"J Asthma"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0255","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/379652a0","article-title":"Creation of a biologically active interleukin-5 monomer","volume":"379","author":"Dickason","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0260","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/BF00204980","article-title":"Engineering of a functional interleukin-5 monomer: A paradigm for redesigning helical bundle cytokines with therapeutic potential in allergy and asthma","volume":"74","author":"Dickason","year":"1996","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0265","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovi\u0107","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0270","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1086\/515322","article-title":"Recombinant human eosinophil-derived neurotoxin\/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus","volume":"177","author":"Domachowske","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0275","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1164\/rccm.200307-1004OC","article-title":"Sputum CD34+ IL-5Ralpha+ cells increase after allergen: Evidence for in situ eosinophilopoiesis","volume":"169","author":"Dorman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0280","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1164\/rccm.200307-1024OC","article-title":"Kinetics of bone marrow eosinophilopoiesis and associated cytokines after allergen inhalation","volume":"169","author":"Dorman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0285","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/thorax.57.7.643","article-title":"Non-eosinophilic asthma: Importance and possible mechanisms","volume":"57","author":"Douwes","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0290","first-page":"69","article-title":"Mature eosinophils stimulated to develop in human cord blood mononuclear cell cultures supplemented with recombinant human interleukin-5. Part I. Piecemeal degranulation of specific granules and distribution of Charcot-Leyden crystal protein","volume":"138","author":"Dvorak","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0295","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000237014","article-title":"Inhibition of pulmonary eosinophilia and hyper-reactivity by antibodies to interleukin-5","volume":"107","author":"Egan","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0300","first-page":"779","article-title":"Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyper-reactivity","volume":"49","author":"Egan","year":"1999","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0305","unstructured":"Ehrlich, P (1878). Beitr\u00e4ge zur Theorie und Praxis der histologischen F\u00e4rbung. Test (Hrsg.), I. Teil: Die chemische Auffassung der F\u00e4rbung. II. Teil: Die Anilinfarben in chemischer, technologischer und histologischer Beziehung [Contributions to the theory and practice of histological staining. Test (Ed.). Part I: The chemical conception of coloring. Part II: The aniline dyes in chemical, technological and histological relationship; dissertation] (Leipzig, Germany; University of Leipzig). 65 pages."},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0310","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1398-9995.2010.02494.x","article-title":"Physical interactions between mast cells and eosinophils: A novel mechanism enhancing eosinophil survival in vitro","volume":"66","author":"Elishmereni","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0315","series-title":"Adverse drug events in U.S. hospitals, 2004: Statistical brief #29. Source: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Health Care Policy and Research (US); 2006\u20132007 April","author":"Elixhauser","year":"2007"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0320","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/ar4594","article-title":"Why is there persistent disease despite biologic therapy?","volume":"16","author":"Emery","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0325","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/annrheumdis-2011-201066","article-title":"Combination etanercept and methotrexate provides better disease control in very early (>4months) versus early rheumatoid arthritis (>4months and <2years): post-hoc analyses from the COMET study","volume":"71","author":"Emery","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0330","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.ijpara.2007.04.001","article-title":"The 434(G>C) polymorphism within the coding sequence of eosinophil cationic protein (ECP) correlates with the natural course of Schistosoma mansoni infection","volume":"37","author":"Eriksson","year":"2007","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0335","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1183\/09031936.98.11061240","article-title":"Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation","volume":"11","author":"Fahy","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0340","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1164\/ajrccm.155.6.9196082","article-title":"The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects","volume":"155","author":"Fahy","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0345","first-page":"295","article-title":"Authors' response to Persson C: Primary lysis\/necrosis of eosinophils and clinical control of asthma","volume":"68","author":"Fattahi","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0350","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0140-6736(82)91152-7","article-title":"Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma","volume":"2","author":"Filley","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0355","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jmb.2011.06.031","article-title":"Whole-molecule antibody engineering: Generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics","volume":"411","author":"Finch","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0365","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0370","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1172\/JCI17974","article-title":"Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics","volume":"112","author":"Flood-Page","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0375","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0380","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.183.1.195","article-title":"Interleukin 5 deficiency abolishes eosinophilia, airways hyper-reactivity, and lung damage in a mouse asthma model","volume":"183","author":"Foster","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0385","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1034\/j.1600-065X.2001.790117.x","article-title":"Elemental signals regulating eosinophil accumulation in the lung","volume":"179","author":"Foster","year":"2001","journal-title":"Immunol Rev"},{"issue":"3 Pt 1","key":"10.1016\/j.pharmthera.2016.10.016_bb0390","first-page":"879","article-title":"Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects","volume":"151","author":"Fraenkel","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0395","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1378\/chest.108.1.48","article-title":"Eosinophil activation in patients with pulmonary fibrosis","volume":"108","author":"Fujimoto","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0400","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.4049\/jimmunol.1400732","article-title":"IL-5 triggers a cooperative cytokine network that promotes eosinophil precursor maturation","volume":"193","author":"Fulkerson","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0405","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1164\/rccm.200902-0166OC","article-title":"The prevalence of nonadherence in difficult asthma","volume":"180","author":"Gamble","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0410","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1164\/rccm.201504-0763PP","article-title":"Evolving concepts of asthma","volume":"192","author":"Gauthier","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0415","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1586\/1744666X.1.1.87","article-title":"Hemopoietic progenitors: The role of eosinophil\/basophil progenitors in allergic airway inflammation","volume":"1","author":"Gauvreau","year":"2005","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0420","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1164\/ajrccm.161.5.9908090","article-title":"Increased numbers of both airway basophils and mast cells in sputum after allergen inhalation challenge of atopic asthmatics","volume":"161","author":"Gauvreau","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0425","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0430","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1359-6101(00)00019-8","article-title":"Specificity in cytokine signal transduction: Lessons learned from the IL-3:IL-5:GM\u2013CSF receptor family","volume":"12","author":"Geijsen","year":"2001","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0435","author":"Global Initiative for Asthma"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0440","author":"Global Initiative for Chronic Obstructive Lung Disease"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0445","series-title":"European Respiratory Society \u2014 20th Annual Congress","first-page":"P1177","article-title":"A multiple ascending subcutaneous (SC) dose study of MEDI- 563, a humanized anti-IL5R\u03b1 monoclonal antibody, in adult asthmatics","author":"Gossage","year":"2010"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0450","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0455","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/thorax.57.10.875","article-title":"Analysis of induced sputum in adults with asthma: Identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids","volume":"57","author":"Green","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0460","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.4049\/jimmunol.170.11.5359","volume":"170","author":"Gregory","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0465","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.immuni.2015.07.008","article-title":"Granulocyte macrophage colony-stimulating factor-activated eosinophils promote interleukin-23 driven chronic colitis","volume":"43","author":"Griseri","year":"2015","journal-title":"Immunity"},{"issue":"2 Pt 1","key":"10.1016\/j.pharmthera.2016.10.016_bb0470","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1164\/ajrccm.156.2.9610079","article-title":"Experimental rhinovirus 16 infection. Effects on cell differentials and soluble markers in sputum in asthmatic subjects","volume":"156","author":"Gr\u00fcnberg","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0475","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0480","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.4049\/jimmunol.144.8.3166","article-title":"In vitro killing of microfilariae of Brugia-Pahangi and Brugia-Malayi by eosinophil granule proteins","volume":"144","author":"Hamann","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0485","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1172\/JCI115166","article-title":"Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma","volume":"87","author":"Hamid","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0490","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0091-6749(95)70298-9","article-title":"Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis","volume":"96","author":"Hamilos","year":"1995","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0495","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0091-6749(93)90035-E","article-title":"Chronic hyperplastic sinusitis: Association of tissue eosinophilia with mRNA expression of granulocyte-macrophage colony-stimulating factor and interleukin-3","volume":"92","author":"Hamilos","year":"1993","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): Replicate, phase 3, randomised, double-blind, placebo-controlled trials","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0505","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","article-title":"Lebrikizumab in moderate-to-severe asthma: Pooled data from two randomised placebo-controlled studies","volume":"70","author":"Hanania","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0510","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: An analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0515","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1067\/mai.2001.116576","article-title":"Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys","volume":"108","author":"Hart","year":"2001","journal-title":"Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0520","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaci.2013.03.044","article-title":"Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects","volume":"132","author":"Hastie","year":"2013","journal-title":"Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0525","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0530","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1172\/JCI115524","article-title":"Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium","volume":"88","author":"Her","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0535","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.4049\/jimmunol.149.11.3642","article-title":"Depletion of eosinophils by anti-IL-5 monoclonal-antibody treatment of mice infected with Trichinella-spiralis does not alter parasite burden or immunological resistance to reinfection","volume":"149","author":"Herndon","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0540","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMoa032158","article-title":"The nature of small-airway obstruction in chronic obstructive pulmonary disease","volume":"350","author":"Hogg","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0545","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1081\/JAS-200063001","article-title":"Eosinophils from asthmatics release IL-5 in an autocrine fashion to prevent apoptosis through upregulation of Bcl-2 expression","volume":"42","author":"Huang","year":"2005","journal-title":"J Asthma"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0550","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1126\/science.1100283","article-title":"A critical role for eosinophils in allergic airways remodeling","volume":"305","author":"Humbles","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0555","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4049\/jimmunol.1101270","article-title":"Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity","volume":"188","author":"Ikutani","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0560","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/aje\/kws181","article-title":"Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: A prospective study of 2 matched cohorts","volume":"176","author":"Iribarren","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0565","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJMoa002304","article-title":"Effects of inhaled glucocorticoids on bone density in premenopausal women","volume":"345","author":"Israel","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0570","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1164\/rccm.201406-1039OC","article-title":"IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo","volume":"190","author":"Jackson","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0575","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.20071840","article-title":"Allergic pulmonary inflammation in mice is dependent on eosinophil-induced recruitment of effector T cells","volume":"205","author":"Jacobsen","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0580","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1183\/09031936.05.00146404","article-title":"Time to death, airway wall inflammation and remodelling in fatal asthma","volume":"26","author":"James","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0585","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1378\/chest.128.3.1140","article-title":"Factors influencing the responsiveness to inhaled glucocorticoids of patients with moderate-to-severe asthma","volume":"128","author":"Jang","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0590","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/ajrccm.161.1.9809100","article-title":"Changes in sputum eosinophils predict loss of asthma control","volume":"161","author":"Jatakanon","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0595","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1183\/09031936.98.12051084","article-title":"An inhaled steroid improves markers of airway inflammation in patients with mild asthma","volume":"12","author":"Jatakanon","year":"1998","journal-title":"Eur Respir J"},{"issue":"5 Pt 1","key":"10.1016\/j.pharmthera.2016.10.016_bb0600","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1164\/ajrccm.160.5.9806170","article-title":"Neutrophilic inflammation in severe persistent asthma","volume":"160","author":"Jatakanon","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0605","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1183\/09031936.06.00137704","article-title":"Determining asthma treatment by monitoring sputum cell counts: Effect on exacerbations","volume":"27","author":"Jayaram","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0610","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jaci.2012.06.025","article-title":"Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients","volume":"130","author":"Jia","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0615","doi-asserted-by":"crossref","first-page":"L16","DOI":"10.1152\/ajplung.00260.2002","article-title":"Ablation of eosinophils leads to a reduction of allergen-induced pulmonary pathology","volume":"284","author":"Justice","year":"2003","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0620","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0091-6749(03)01870-0","article-title":"Potential adverse effects of inhaled corticosteroids","volume":"112","author":"Kelly","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0625","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005374","article-title":"TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation","volume":"5","author":"Kim","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0630","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.coi.2013.07.013","article-title":"Innate lymphoid cells and allergic inflammation","volume":"25","author":"Kim","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0635","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1067\/mai.2003.1618","article-title":"Bronchoalveolar lavage cytokine profiles in acute asthma and acute bronchiolitis","volume":"112","author":"Kim","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0640","author":"King"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0645","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","article-title":"Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: A pilot study","volume":"167","author":"Kips","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0650","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-interleukin 5 receptor-alpha monoclonal antibody, with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0655","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1254\/jphs.09277FP","article-title":"A novel CC-chemokine receptor 3 antagonist, Ki19003, inhibits airway eosinophilia and subepithelial\/peribronchial fibrosis induced by repeated antigen challenge in mice","volume":"112","author":"Komai","year":"2010","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0660","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0665","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1164\/rccm.200403-409OC","article-title":"Corticosteroid use after hospital discharge among high-risk adults with asthma","volume":"170","author":"Krishnan","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0670","series-title":"Eosinophils in health and disease","first-page":"206","article-title":"Signaling and degranulation chapter","author":"Lacy","year":"2012"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0675","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1034\/j.1399-3003.2000.15.14.x","article-title":"Subepithelial immunopathology of the large airways in smokers with and without chronic obstructive pulmonary disease","volume":"15","author":"Lams","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0680","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1411532","article-title":"Lung-function trajectories leading to chronic obstructive pulmonary disease","volume":"373","author":"Lange","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0685","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jaci.2013.12.1081","article-title":"Mechanisms of human eosinophil migration induced by the combination of IL-5 and the endocannabinoid 2-arachidonoyl-glycerol","volume":"133","author":"Larose","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0690","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0695","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0700","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1126\/science.1099472","article-title":"Defining a link with asthma in mice congenitally deficient in eosinophils","volume":"305","author":"Lee","year":"2004","journal-title":"Science"},{"issue":"4 Pt 1","key":"10.1016\/j.pharmthera.2016.10.016_bb0705","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0091-6749(99)70288-5","article-title":"Elevated plasma eotaxin levels in patients with acute asthma","volume":"104","author":"Lilly","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0710","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1164\/ajrccm.159.1.9706006","article-title":"Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma","volume":"159","author":"Lim","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0715","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.4049\/jimmunol.162.6.3639","article-title":"Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes","volume":"162","author":"Liu","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0720","doi-asserted-by":"crossref","first-page":"6452","DOI":"10.4049\/jimmunol.169.11.6452","article-title":"Decreased expression of membrane IL-5 receptor alpha on human eosinophils. I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge","volume":"169","author":"Liu","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0730","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1084\/jem.163.5.1085","article-title":"Murine eosinophil differentiation factor. An eosinophil-specific colony-stimulating factor with activity for human cells","volume":"163","author":"Lopez","year":"1986","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0735","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1084\/jem.167.1.219","article-title":"Recombinant human interleukin 5 is a selective activator of human eosinophil function","volume":"167","author":"Lopez","year":"1988","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0740","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/01.cji.0000211324.53396.f6","article-title":"Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): Role in the inflammatory response within tumours","volume":"30","author":"Lotfi","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0745","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2010.11.037","article-title":"Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome","volume":"127","author":"L\u00f6tvall","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0750","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1164\/ajrccm.161.1.9802048","article-title":"The relationship between airways inflammation and asthma severity","volume":"161","author":"Louis","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0755","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jmb.2010.12.017","article-title":"Engineering a high-affinity anti-IL-15 antibody: Crystal structure reveals an \u03b1-helix in VH CDR3 as key component of paratope","volume":"406","author":"Lowe","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0760","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-3083.2009.02363.x","article-title":"New production of eosinophils and the corresponding TH1\/TH2 balance in the lungs after allergen exposure in BALB\/c and C57BL\/6 mice","volume":"71","author":"Lu","year":"2010","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0765","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11882-002-0007-0","article-title":"Basophils in airway disease","volume":"2","author":"MacGlashan","year":"2002","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0770","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1124\/jpet.106.110734","article-title":"A potent human anti-eotaxin1 antibody, CAT-213: Isolation by phage display and in vitro and in vivo efficacy","volume":"319","author":"Main","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0775","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jaci.2013.06.007","article-title":"Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects","volume":"132","author":"Malinovschi","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0780","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.rmed.2009.01.003","article-title":"The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use","volume":"103","author":"Manson","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0785","unstructured":"Martin, J. H., Huang, T. T., Fairhurst, J. L., & Papadopoulos, N. J., inventors; assignee: Regeneron Pharmaceuticals, Inc. (2009). High affinity human antibodies to IL-4 receptor. Patent US7608693B2. 2009, October 27."},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0790","author":"Masoli"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0795","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.rmed.2009.09.011","article-title":"Effect of omalizumab on peripheral blood eosinophilia in allergic asthma","volume":"104","author":"Massanari","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0800","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cyto.2015.05.018","article-title":"Strategies targeting the IL-4\/IL-13 axes in disease","volume":"75","author":"May","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0805","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1476-5381.2011.01659.x","article-title":"Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma","volume":"166","author":"May","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0810","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1164\/rccm.201109-1640OC","article-title":"A large subgroup of mild-to-moderate asthma is persistently noneosinophilic","volume":"185","author":"McGrath","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0815","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.4049\/jimmunol.156.11.4422","article-title":"Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes","volume":"156","author":"Meagher","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0820","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/thx.54.10.894","article-title":"Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma","volume":"54","author":"Meijer","year":"1999","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0825","first-page":"1341","article-title":"Piecemeal degranulation in human eosinophils: A distinct secretion mechanism underlying inflammatory responses","volume":"25","author":"Melo","year":"2010","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0830","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1742-7843.2005.pto960307.x","article-title":"On the prediction of the human response: A recycled mechanistic pharmacokinetic\/pharmacodynamic approach","volume":"96","author":"Meno-Tetang","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0835","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1067\/mai.2003.1382","article-title":"Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics","volume":"111","author":"Menzies-Gow","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0840","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/363172a0","article-title":"A novel dimer configuration revealed by the crystal structure at 2.4A resolution of human interleukin-5","volume":"363","author":"Milburn","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0845","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1165\/ajrcmb.17.3.2733","article-title":"Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma","volume":"17","author":"Minshall","year":"1997","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0850","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2003.10.041","article-title":"Distinguishing severe asthma phenotypes: Role of age at onset and eosinophilic inflammation","volume":"113","author":"Miranda","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0855","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ni.2104","article-title":"Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161","volume":"12","author":"Mjosberg","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0860","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00198-015-3089-y","article-title":"Impact of treatment with inhaled corticosteroids on bone mineral density of patients with asthma: Related with age","volume":"26","author":"Monadi","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0865","unstructured":"Monk, P. D., Jermutus, L., Minter, R. R., & Shorrock, C.P. (2005). Human Antibody Molecules for IL-13. Patent WO\/2005\/007699. 2005, January 27."},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0870","first-page":"1","article-title":"National surveillance for asthma \u2014 United States, 1980\u20132004","volume":"56","author":"Moorman","year":"2007","journal-title":"MMWR Surveill Summ"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0875","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1084\/jem.20081756","article-title":"Identification of the human eosinophil lineage-committed progenitor: Revision of phenotypic definition of the human common myeloid progenitor","volume":"206","author":"Mori","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0880","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1172\/JCI119234","article-title":"Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice","volume":"99","author":"Mould","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0885","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0083-6729(06)74001-8","article-title":"IL-3, IL-5, and GM\u2013CSF signaling: Crystal structure of the human beta-common receptor","volume":"74","author":"Murphy","year":"2006","journal-title":"Vitam Horm"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0890","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/thoraxjnl-2011-201096","article-title":"The relationship between clinical outcomes and medication adherence in difficult-to-control asthma","volume":"67","author":"Murphy","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0895","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0900","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/cea.12244","article-title":"Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: A randomized, placebo-controlled clinical trial","volume":"44","author":"Neighbour","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0905","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/nature08900","article-title":"Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity","volume":"464","author":"Neill","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0910","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.coi.2009.07.011","article-title":"Functional extracellular eosinophil granules: Novel implications in eosinophil immunobiology","volume":"21","author":"Neves","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0915","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1182\/blood.V88.7.2458.bloodjournal8872458","article-title":"Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor\/interleukin-3\/interleukin-5 functions","volume":"88","author":"Nishinakamura","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0920","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2013.03.051","article-title":"Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids","volume":"132","author":"Noonan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0925","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ajem.2014.09.036","article-title":"A randomized trial of benralizumab, an antiinterleukin 5 receptor \u03b1 monoclonal antibody, after acute asthma","volume":"33","author":"Nowak","year":"2015","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0930","author":"Nucala [United States package insert]"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0935","author":"Nucala European Union Summary of Product Characteristics [labeling information]"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0940","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1046\/j.1365-2249.1997.d01-884.x","article-title":"IL-5 but not interferon gamma (IFN-gamma) inhibits eosinophil apoptosis by up-regulation of bcl-2 expression","volume":"107","author":"Ochiai","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0945","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"MENSA investigators. Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: A secondary analysis of the DREAM and MENSA studies","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0955","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1874306401408010059","article-title":"Systemic effects of inhaled corticosteroids: An overview","volume":"8","author":"Pandya","year":"2014","journal-title":"Open Respir Med J"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0960","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(99)01813-9","article-title":"Non-eosinophilic corticosteroid unresponsive asthma","volume":"353","author":"Pavord","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0965","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0970","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1471-4892(01)00044-3","article-title":"Eotaxin and asthma","volume":"1","author":"Pease","year":"2001","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0975","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1164\/rccm.201311-2069OE","article-title":"Theirs but to die and do: Primary lysis of eosinophils and free eosinophil granules in asthma","volume":"189","author":"Persson","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0980","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.rmed.2016.01.003","article-title":"Reductions in eosinophil biomarkers by benralizumab in patients with asthma","volume":"111","author":"Pham","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0985","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2007-01-071340","article-title":"Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus","volume":"110","author":"Phipps","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0990","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.00223411","article-title":"A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma","volume":"41","author":"Piper","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb0995","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1164\/ajrccm.155.5.9154849","article-title":"Sputum in severe exacerbations of asthma: Kinetics of inflammatory indices after prednisone treatment","volume":"155","author":"Pizzichini","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1000","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1183\/09031936.99.13101599","article-title":"Prednisone-dependent asthma: Inflammatory indices in induced sputum","volume":"13","author":"Pizzichini","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1005","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010834.pub2","article-title":"Mepolizumab versus placebo for asthma","volume":"7","author":"Powell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1010","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.cell.2014.03.066","article-title":"Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat","volume":"157","author":"Qiu","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1015","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.pharmthera.2008.10.008","article-title":"Eosinophil progenitors in allergy and asthma \u2014 Do they matter?","volume":"121","author":"R\u00e5dinger","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1020","first-page":"54","article-title":"Interleukin-13 signaling and its role in asthma","volume":"4","author":"Rael","year":"2011","journal-title":"WAO J"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1365-3024.1998.00132.x","article-title":"Eosinophil-mediated killing of Haemonchus contortus larvae: Effect of eosinophil activation and role of antibody, complement and interleukin-5","volume":"20","author":"Rainbird","year":"1998","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/MCP.0b013e3282f1982d","article-title":"Near-fatal asthma: Recognition and management","volume":"14","author":"Restrepo","year":"2008","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1035","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/039463201202500217","article-title":"Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients","volume":"25","author":"Riccio","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1040","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc modified humanized monoclonal antibody, motavizumab YTE, has an extended half-life in healthy adults: A randomized study","volume":"57","author":"Robbie","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1165\/ajrcmb.20.1.3449","article-title":"CD34(+)\/interleukin-5Ralpha messenger RNA+ cells in the bronchial mucosa in asthma: Potential airway eosinophil progenitors","volume":"20","author":"Robinson","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2\u20134","key":"10.1016\/j.pharmthera.2016.10.016_bb1050","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000024039","article-title":"Eosinophil development and bone marrow and tissue eosinophils in atopic asthma","volume":"118","author":"Robinson","year":"1999","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1060","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1378\/chest.130.5.1301","article-title":"Rapid effects of inhaled corticosteroids in acute asthma: An evidence-based evaluation","volume":"130","author":"Rodrigo","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1065","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: The neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nri3341","article-title":"Eosinophils: Changing perspectives in health and disease","volume":"13","author":"Rosenberg","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1075","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/blood.V95.8.2491","article-title":"Structure of the activation domain of the GM\u2013CSF\/IL-3\/IL-5 receptor common beta-chain bound to an antagonist","volume":"95","author":"Rossjohn","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1080","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"issue":"6 Pt 1","key":"10.1016\/j.pharmthera.2016.10.016_bb1085","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1164\/ajrccm.150.6.7952628","article-title":"Airway eosinophilia in chronic bronchitis during exacerbations","volume":"150","author":"Saetta","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1090","first-page":"39","article-title":"Eosinophilic airway inflammation in COPD","volume":"1","author":"Saha","year":"2006","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1095","article-title":"Expression of activation markers in circulating basophils and the relationship to allergen-induced bronchoconstriction in subjects with mild allergic asthma","author":"Salter","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1100","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood.V79.12.3101.bloodjournal79123101","article-title":"Interleukin-5, eosinophils, and disease","volume":"79","author":"Sanderson","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1105","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: A systematic literature review","volume":"10","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/cea.12220","article-title":"The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge","volume":"44","author":"Scheerens","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1183\/09031936.00201813","article-title":"Importance of concomitant local and systemic eosinophilia in uncontrolled asthma","volume":"44","author":"Schleich","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2466-13-11","article-title":"Distribution of sputum cellular phenotype in a large asthma cohort: Predicting factors for eosinophilic vs neutrophilic inflammation","volume":"13","author":"Schleich","year":"2013","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1125","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-2006-939515","article-title":"Eosinophilic airway disorders","volume":"27","author":"Scott","year":"2006","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1130","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/blood.V79.11.2952.bloodjournal79112952","article-title":"Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects","volume":"79","author":"Sehmi","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1135","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0008-8749(95)80008-7","article-title":"Modulation of growth and differentiation of eosinophils from human peripheral blood CD34+ cells by IL5 and other growth factors","volume":"160","author":"Shalit","year":"1995","journal-title":"Cell Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1140","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s10495-014-1072-2","article-title":"Determinants of eosinophil survival and apoptotic cell death","volume":"20","author":"Shen","year":"2015","journal-title":"Apoptosis"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1145","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.4049\/jimmunol.145.11.3911","article-title":"Ablation of eosinophil and IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma-Mansoni in the mouse","volume":"145","author":"Sher","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1150","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1164\/ajrccm.157.1.9703027","article-title":"Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics","volume":"157","author":"Shi","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2016.10.016_bb1155","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000237717","article-title":"Protective roles of eosinophils in Nippostrongylus brasiliensis infection","volume":"114","author":"Shin","year":"1997","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-3024.2001.00352.x","article-title":"Involvement of complement and fibronectin in eosinophil-mediated damage to Nippostrongylus brasiliensis larvae","volume":"23","author":"Shin","year":"2001","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1165","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0167-5699(95)80086-7","article-title":"Inhibition of programmed eosinophil death: A key pathogenic event for eosinophilia?","volume":"16","author":"Simon","year":"1995","journal-title":"Immunol Today"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1170","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1002\/eji.1830271256","article-title":"Anti-apoptotic signals of granulocyte-macrophage colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophils","volume":"27","author":"Simon","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1175","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1183\/09031936.00146306","article-title":"Eosinophilic airway inflammation and exacerbations of COPD: A randomised controlled trial","volume":"29","author":"Siva","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1180","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5114\/pdia.2014.40973","article-title":"Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbation","volume":"31","author":"Skiepko","year":"2014","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1185","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jaci.2014.12.1918","article-title":"Thymic stromal lymphopoietin and IL-33 modulate migration of hematopoietic progenitor cells in patients with allergic asthma","volume":"135","author":"Smith","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1190","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/11584340-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody","volume":"50","author":"Smith","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1195","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Sol\u00e8r","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1200","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/19420862.2015.1054585","article-title":"A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life","volume":"7","author":"Souders","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1205","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jaci.2004.09.022","article-title":"Increased eosinophil-lineage committed progenitors in the lung of allergen-challenged mice","volume":"115","author":"Southam","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1210","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1189\/jlb.0108058","article-title":"Human eosinophils constitutively express multiple Th1, Th2 and immunoregulatory cytokines that are secreted rapidly and differentially","volume":"85","author":"Spencer","year":"2009","journal-title":"J Leukoc Biol"},{"issue":"2 Pt A","key":"10.1016\/j.pharmthera.2016.10.016_bb1215","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1220","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1164\/ajrccm.154.1.8680684","article-title":"Cellular infiltration of the airways in asthma of varying severity","volume":"154","author":"Synek","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2016.10.016_bb1225","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000350852","article-title":"Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma","volume":"161","author":"Takaku","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1230","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1165\/rcmb.2003-0305OC","article-title":"Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice","volume":"31","author":"Tanaka","year":"2004","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1235","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/0092-8674(91)90040-6","article-title":"A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM\u2013CSF","volume":"66","author":"Tavernier","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1240","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1164\/ajrccm.164.5.2011026","article-title":"Factors associated with persistent airflow limitation in severe asthma","volume":"164","author":"ten Brinke","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1245","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.anai.2014.04.011","article-title":"High blood eosinophil count is associated with more frequent asthma attacks in asthma patients","volume":"113","author":"Tran","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1250","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.anai.2015.10.027","article-title":"Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma","volume":"116","author":"Tran","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1255","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.tips.2006.07.006","article-title":"Resolution of airway disease: Removal of inflammatory cells through apoptosis, egression or both?","volume":"27","author":"Uller","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1260","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1465-9921-6-90","article-title":"Anti-Fas mAb-induced apoptosis and cytolysis of airway tissue eosinophils aggravates rather than resolves established inflammation","volume":"6","author":"Uller","year":"2005","journal-title":"Respir Res"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1265","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1378\/chest.108.1.10","article-title":"Mortality and markers of risk of asthma death among 1,075 outpatients with asthma","volume":"108","author":"Ulrik","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1270","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jmb.2013.01.024","article-title":"Structural basis of signaling blockade by anti-IL-13 antibody lebrikizumab","volume":"425","author":"Ultsch","year":"2013","journal-title":"J Mol Biol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1275","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-06-0066","article-title":"Complement induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity","volume":"12","author":"van Meerten","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1280","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/thx.54.5.403","article-title":"Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma","volume":"54","author":"van Rensen","year":"1999","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1285","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jaci.2009.06.029","article-title":"Consistency of sputum eosinophilia in difficult-to-treat asthma: A 5-year follow-up study","volume":"124","author":"van Veen","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1290","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1164\/ajrccm.156.2.9609066","article-title":"Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis","volume":"156","author":"Vignola","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1295","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/thoraxjnl-2012-201861","article-title":"Clinical control of asthma associates with measures of airway inflammation","volume":"68","author":"Volbeda","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1300","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/thoraxjnl-2014-205634","article-title":"External validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthma","volume":"70","author":"Wagener","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1305","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/imt.13.118","article-title":"An update on biologic-based therapy in asthma","volume":"5","author":"Walsh","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1310","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.4049\/jimmunol.179.11.7585","article-title":"Airway eosinophils: Allergic inflammation recruited professional antigen-presenting cells","volume":"179","author":"Wang","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1315","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaci.2012.07.027","article-title":"Novel targeted therapies for eosinophilic disorders","volume":"130","author":"Wechsler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1320","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1165\/rcmb.2006-0188OC","article-title":"Effects of a low-molecular-weight CCR-3 antagonist on chronic experimental asthma","volume":"36","author":"Wegmann","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1325","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1073\/pnas.1220572110","article-title":"Eosinophil adoptive transfer system to directly evaluate pulmonary eosinophil trafficking in vivo","volume":"110","author":"Wen","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1330","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1164\/rccm.200409-1181PP","article-title":"Severe asthma in adults","volume":"172","author":"Wenzel","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1335","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: The evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1340","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.pupt.2013.07.003","article-title":"Complex phenotypes in asthma: Current definitions","volume":"26","author":"Wenzel","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1345","doi-asserted-by":"crossref","DOI":"10.1165\/rcmb.2016-0141PS","article-title":"Emergence of biomolecular pathways to define novel asthma phenotypes: Type-2 immunity and beyond","author":"Wenzel","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1350","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1355","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1360","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/ajrccm.160.3.9812110","article-title":"Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics","volume":"160","author":"Wenzel","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1365","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/0009922812461441","article-title":"Parental preference for short- versus long-course corticosteroid therapy in children with asthma presenting to the pediatric emergency department","volume":"52","author":"Williams","year":"2013","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1370","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jaci.2004.09.028","article-title":"Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma","volume":"114","author":"Williams","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1375","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/cea.12156","article-title":"The relationship between eosinophilia and airway remodelling in mild asthma","volume":"43","author":"Wilson","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1380","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1165\/rcmb.2009-0168OC","article-title":"Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: Implications in allergic inflammation","volume":"43","author":"Wong","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1385","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(00)02138-3","article-title":"Inhaled corticosteroid use and bone-mineral density in patients with asthma","volume":"355","author":"Wong","year":"2000","journal-title":"Lancet"},{"issue":"40","key":"10.1016\/j.pharmthera.2016.10.016_bb1390","doi-asserted-by":"crossref","first-page":"15858","DOI":"10.1073\/pnas.0707413104","article-title":"Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids","volume":"104","author":"Woodruff","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1395","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1400","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1164\/ajrccm.151.6.7767540","article-title":"Effects of allergen challenge on eosinophils, eosinophil cationic protein, and granulocyte-macrophage colony-stimulating factor in mild asthma","volume":"151","author":"Woolley","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1405","author":"World Health Organization"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1410","author":"World Health Organization"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1415","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1513\/AnnalsATS.201410-459OC","article-title":"Primary adherence to controller medications for asthma is poor","volume":"12","author":"Wu","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1420","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1126\/science.1201475","article-title":"Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis","volume":"332","author":"Wu","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1425","author":"Xolair [European Union Summary of Product Characteristics]"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1430","author":"Xolair [United States package insert]"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1435","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1034\/j.1398-9995.2000.00474.x","article-title":"Eotaxin in induced sputum of asthmatics: Relationship with eosinophils and eosinophil cationic protein in sputum","volume":"55","author":"Yamada","year":"2000","journal-title":"Allergy"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1440","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.4049\/jimmunol.163.11.6321","article-title":"Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics","volume":"163","author":"Ying","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1445","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1002\/eji.1830271252","article-title":"Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells","volume":"27","author":"Ying","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1450","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1084\/jem.183.4.1407","article-title":"Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils","volume":"183","author":"Yousefi","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1455","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1006\/cyto.2002.1972","article-title":"Analysis of novel disease-related genes in bronchial asthma","volume":"19","author":"Yuyama","year":"2002","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1460","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2249.2004.02396.x","article-title":"The effect of eosinophils on collagen gel contraction and implications for tissue remodelling","volume":"135","author":"Zagai","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1465","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2500\/aap.2015.36.3863","article-title":"Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use","volume":"36","author":"Zazzali","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1470","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jaip.2014.06.005","article-title":"High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma","volume":"2","author":"Zeiger","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1475","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.iac.2007.09.003","article-title":"Tissue and BAL based biomarkers in asthma","volume":"27","author":"Zhang","year":"2007","journal-title":"Immunol Allergy Clin N Am"},{"key":"10.1016\/j.pharmthera.2016.10.016_bb1480","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1164\/ajrccm.164.1.2007050","article-title":"Exacerbations of bronchitis: Bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants","volume":"164","author":"Zhu","year":"2001","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816301954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816301954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T11:07:31Z","timestamp":1692529651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725816301954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":294,"alternative-id":["S0163725816301954"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.10.016","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 AstraZeneca. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}